Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syndax Pharmaceuticals has begun Phase I/II study of entinostat in combination with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab.
Subscribe to our email newsletter
The Phase I study will illustrate the safety profile of the combination and identify the appropriate dosing regimen to be used in the Phase II portion.
Translational studies will evaluate the mechanism of action for the combination in tumor cells while identifying biomarkers for patient selection in subsequent studies.
Syndax president and chief executive officer Joanna Horobin said: "With our recently reported positive data in ENCORE 301 targeting ER+ breast cancer and the NCI sponsored study NCT01234532 combining entinostat with Arimidex in ER-, PR-, HER2- triple negative breast cancer we are pleased to be in a position to provide proof-of-concept clinical data across all segments of breast cancer."